World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
118
Citations
87039
World Ranking
3964
National Ranking
5

Dong-Wan Kim publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dong-Wan Kim sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,052 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dong-Wan Kim D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dong-Wan Kim sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award
  • 2025 - Research.com Medicine in Korea Leader Award
  • 2023 - Research.com Medicine in Korea Leader Award
  • 2022 - Research.com Medicine in Korea Leader Award

Overview

Dong-Wan Kim is affiliated with Seoul National University Hospital in South Korea and has a primary research focus on engineering, with a specialization in electrical and electronic engineering. Their scholarly work spans various subfields including renewable energy, sustainability and the environment, materials chemistry, electronic, optical and magnetic materials, and automotive engineering.

Their research emphasizes advanced battery materials and technologies, a topic they have extensively contributed to through numerous publications. Core themes in their work include advancements in battery materials, advanced battery technologies research, electrocatalysts for energy conversion, supercapacitor materials and fabrication, and fuel cells and related materials.

Key papers authored or co-authored by Dong-Wan Kim cover a range of topics and years, including:

  • Repeated-oral dose toxicity of polyethylene microplastics and the possible implications on reproduction and development of the next generation (2020, Toxicology Letters)
  • Highly Efficient Perovskite-Based Electrocatalysts for Water Oxidation in Acidic Environments: A Mini Review (2020, Advanced Energy Materials)
  • Porous Lithiophilic Li-Si Alloy-Type Interfacial Framework via Self-Discharge Mechanism for Stable Lithium Metal Anode with Superior Rate (2021, Advanced Energy Materials)
  • Peroxymonosulfate activation by carbon-encapsulated metal nanoparticles: Switching the primary reaction route and increasing chemical stability (2020, Applied Catalysis B: Environmental)
  • Synergistic Design of Multifunctional Interfacial Zn Host toward Practical Zn Metal Batteries (2022, Advanced Energy Materials)

Dong-Wan Kim has frequently published in several scientific journals, with the highest number of publications appearing in:

  • Advanced Energy Materials (15 publications)
  • International Journal of Energy Research (14 publications)
  • Chemical Engineering Journal (13 publications)
  • Journal of Materials Chemistry A (6 publications)
  • Applied Catalysis B: Environmental (5 publications)

The scientist has collaborated regularly with a group of co-authors, including:

  • Gwang-Hee Lee (27 co-authored works)
  • Changhoon Choi (22 co-authored works)
  • Hyunseok Yoon (15 co-authored works)
  • Myeong-Chang Sung (15 co-authored works)
  • Hee Jo Song (14 co-authored works)

Best Publications

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes

    Ki Tae Nam;Dong Wan Kim;Pil J. Yoo;Chung Yi Chiang

  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

    Darren A.E. Cross;Susan E. Ashton;Serban Ghiorghiu;Cath Eberlein

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

    Tae You Kim;Dong-Wan Kim;Jae-Yong Chung;Sang Goo Shin

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Todd M. Bauer;Filippo de Marinis;Enriqueta Felip

  • Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

    Sai Hong Ignatius Ou;Jin Seok Ahn;Luigi De Petris;Ramaswamy Govindan

  • Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

    June Chul Lee;Kyung Mi Lee;Dong Wan Kim;Dae Seog Heo

  • Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

    Peter Ballard;James W.T. Yates;Zhenfan Yang;Dong-Wan Kim

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

    Sai Hong Ignatius Ou;Eunice L. Kwak;Christina Siwak-Tapp;Joni Dy

  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

    James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

Frequent Co-Authors

Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Alice T. Shaw
Alice T. Shaw Harvard University
Doo Hyun Chung
Doo Hyun Chung Seoul National University
Yoon Kyung Jeon
Yoon Kyung Jeon Seoul National University Hospital
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is just one of many pathways within healthcare. If you’re considering a flexible or alternative route to a medical career, several fully online degrees can help you build skills and advance in this growing field.

Future leaders in healthcare management may want to explore the cheapest mha online programs, which offer a cost-effective way to gain the credentials needed for administrative roles. Nurses seeking the highest level of clinical practice might consider enrolling in one of the least expensive dnp programs to become nurse practitioners or advanced practice specialists.

If your interest lies in pharmacy, there are now quality pharmd online programs designed for aspiring pharmacists who need scheduling flexibility or live far from an accredited campus. For those who prefer the intersection of technology and healthcare, a bachelor of health information management online opens doors to roles in medical records, data analysis, and healthcare IT.

Each path has unique prerequisites, career outcomes, and admission requirements. These related online degrees can offer new avenues for healthcare impact — even if you don’t take the traditional route through medical school in the USA.

Best Scientists Citing Dong-Wan Kim

Trending Scientists

Recently Published Articles